No (%) | |
CTCAE grade | |
2 | 11 (42.3) |
3 | 13 (50.0) |
4 | 2 (7.7) |
Refractory/resistant | |
Steroid refractory | 12 (46.2) |
Steroid resistant | 14 (53.8) |
Maximum steroid dose, prednisone equivalent | |
Range (median) | 30–1250 mg (100 mg) |
≥60 mg* | 21 (80.7) |
Additional Immune modulator | |
TNF antagonist | 21 (80.8) |
Mycophenolate mofetil | 9 (34.6) |
Cyclophosphamide | 1 (3.8) |
>1 | 5 (19.2) |
Response to additional immune modulator | |
Durable improvement | 10 (38.5) |
Transient improvement | 13 (50.0) |
No improvement | 3 (11.5) |
Outcomes | |
Mortality due to pneumonitis | 6 (23.1) |
Mortality due to infection | 3 (11.5) |
*All patients with steroid refractory pneumonitis were treated with ≥60 mg.
CTCAE, common terminology criteria for adverse events; TNF, tumor necrosis factor.